Welcome to our dedicated page for Imunon news (Ticker: $IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Imunon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Imunon's position in the market.
Rhea-AI Summary
IMUNON, Inc. files IND application for Phase 1 study of IMNN-101 COVID-19 booster vaccine using DNA-based technology. The study aims to evaluate safety, durability, and immune response superiority over mRNA vaccines. Enrollment expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
-
Rhea-AI Summary
IMUNON, Inc. announces the resignation of Dr. Corinne Le Goff as President and CEO, with Executive Chairman Michael H. Tardugno assuming day-to-day operations. The company remains focused on key milestones for its drug-development programs, with upcoming Phase 1 studies and topline data releases expected. An active search for a new CEO is underway, and financial results for 2023 will be reported soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (IMNN) reports positive results from a murine study conducted by the Wistar Institute with their IMNN-101 vaccine against the SARS-CoV-2 variant XBB.1.5. The study showed immunogenicity and protective activity in mice, with higher T-cell responses compared to mRNA vaccines. IMNN-101 demonstrated stability at refrigerated temperatures for at least four weeks and elicited robust IgG and neutralizing antibody responses. The vaccine provided complete protection in mice challenged with live virus 21 days after the second vaccination. IMUNON's PlaCCine technology presents itself as a promising alternative to mRNA vaccines, with comparable or superior protection against SARS-CoV-2 and enhanced storage benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.33%
Tags
Rhea-AI Summary
IMUNON, Inc. announces a Phase 1/2 clinical trial with Memorial Sloan Kettering Cancer Center evaluating IMNN-001 in combination with bevacizumab for advanced ovarian cancer. The trial aims to detect minimal residual disease and improve progression-free survival, potentially revolutionizing ovarian cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.39%
Tags
-
Rhea-AI Summary
IMUNON, Inc. announces strong immunogenicity and protection with its PlaCCine DNA-based vaccine modality. The study published in the peer-reviewed journal Vaccine demonstrates the effectiveness of IMUNON's proprietary formulation against SARS-CoV-2 variants, highlighting stable DNA vaccine products, induction of neutralizing antibodies and cytotoxic T cells, and suppression of viral replication. IMUNON plans to file an IND application with the FDA and start a Phase 1/2 study soon, aiming to provide potent and durable immunity against COVID-19.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (NASDAQ: IMNN) appoints Sebastien Hazard, M.D. as Chief Medical Officer to lead clinical programs in ovarian cancer and infectious diseases. Dr. Hazard brings 25 years of drug development and commercialization experience, including extensive oncology background. IMUNON prepares to report topline data in Q2 2024 from the OVATION 2 Study with IMNN-001, a gene-mediated IL-2 immunotherapy. The company also approved an inducement option and restricted inducement stock grant for Dr. Hazard.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
Rhea-AI Summary
IMUNON, Inc. (NASDAQ: IMNN) announces Dr. Jean Boyer's presentation at the Vaccines Summit-2023, highlighting the advantages of IMUNON’s PlaCCine modality for vaccine development. The presentation includes updated data on the PlaCCine SARS-CoV-2 DNA vaccine, demonstrating robust immunogenicity, spike-specific immune responses in mice and primates, and reduction of lung viral loads by more than 90%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (NASDAQ: IMNN) announced financial results for the three and nine months ended September 30, 2023. The Company provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line locally advanced ovarian cancer; on its PlaCCine modality, a proprietary mono- or multi-cistronic non-viral and synthetic DNA technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines; and on the early developments with its new FixPlas modality for cancer vaccines. The highlights include promising interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001, the enrollment of the first patient in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab in advanced ovarian cancer, and continued progress towards submitting an Investigational New Drug (IND) application for IMNN-101, a seasonal COVID-19 booster vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
-
Rhea-AI Summary
IMUNON, Inc. (NASDAQ: IMNN) will host a conference call to discuss financial results for the third quarter and nine-months ended September 30, 2023, as well as provide an update on its clinical development of IMNN-001 and preclinical studies of PLACCINE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Rhea-AI Summary
IMUNON to highlight advantages of PlaCCine modality at International Vaccines Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
Imunon, Inc.
Nasdaq:IMNN
IMNN Rankings
IMNN Stock Data
13.35M
9.37M
1.15%
4.47%
4.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
LAWRENCEVILLE
About IMNN
celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.